Finally, while our experimental validation employed an LDLR−/− atherosclerosis mouse model, this approach was selected based on atherosclerosis being the predominant underlying pathology in CHD, accounting for the majority of cases in our clinical cohort. The gene discussed is LDLR; the disease is atherosclerosis.